Zevra Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jul '25 Jul 3, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	533	445	272	158	308	48	Upgrade
Market Cap Growth	68.25%	63.82%	71.57%	-48.52%	536.60%	283.47%	Upgrade
Enterprise Value	532	416	233	97	178	112	Upgrade
Last Close Price	9.74	8.34	6.55	4.59	8.71	11.20	Upgrade
Forward PE	9.15	-	-	-	-	2.95	Upgrade
PS Ratio	11.84	18.85	9.90	15.59	10.74	3.64	Upgrade
PB Ratio	12.98	11.22	4.39	2.11	2.42	-0.73	Upgrade
P/TBV Ratio	-	-	-	2.11	2.42	-	Upgrade
P/FCF Ratio	-	-	-	-	29.76	-	Upgrade
P/OCF Ratio	-	-	-	-	29.47	-	Upgrade
EV/Sales Ratio	13.10	17.61	8.49	9.52	6.21	8.43	Upgrade
EV/EBITDA Ratio	-	-	-	-	22.27	-	Upgrade
EV/EBIT Ratio	-	-	-	-	23.01	-	Upgrade
EV/FCF Ratio	-	-	-	-	17.20	-	Upgrade
Debt / Equity Ratio	1.51	1.52	0.71	0.19	0.01	-1.06	Upgrade
Debt / EBITDA Ratio	-	-	-	-	0.18	-	Upgrade
Debt / FCF Ratio	-	-	-	-	0.16	-	Upgrade
Asset Turnover	0.25	0.14	0.19	0.08	0.40	1.22	Upgrade
Quick Ratio	2.79	2.35	1.16	7.58	26.92	0.90	Upgrade
Current Ratio	3.02	2.53	1.18	7.72	27.20	1.11	Upgrade
Return on Equity (ROE)	-204.78%	-207.84%	-67.23%	-26.48%	-28.18%	-	Upgrade
Return on Assets (ROA)	-27.73%	-31.03%	-21.55%	-12.54%	6.70%	-27.52%	Upgrade
Return on Capital (ROIC)	-45.85%	-52.90%	-31.82%	-14.28%	7.27%	-62.18%	Upgrade
Return on Capital Employed (ROCE)	-	-	-	-	6.00%	-	Upgrade
Earnings Yield	-17.27%	-23.70%	-16.95%	-16.90%	-2.78%	-26.41%	Upgrade
FCF Yield	-11.61%	-15.65%	-12.45%	-11.88%	3.36%	-4.08%	Upgrade
Buyback Yield / Dilution	-32.32%	-30.46%	-2.79%	-15.87%	-647.72%	-114.79%	Upgrade

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q